Vikas Lifecare’s in-house R&D Unit gets DSIR recognition
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Subscribe To Our Newsletter & Stay Updated